Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00425126 · ClinicalTrials.gov registry record · Phase 4
Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation
A Phase 4 study of Delayed Graft Function, sponsored by West Penn Allegheny Health System.
- Completed
- Registry status
- Phase 4
- Development phase
- 76
- Enrollment target
- 1
- Study location
NCT00425126 is a Phase 4 study of Delayed Graft Function that has completed, run by West Penn Allegheny Health System. The registered enrollment target is 76 participants, below the 362-participant average among 6 other Delayed Graft Function trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00425126, a Phase 4 study of Delayed Graft Function, has completed, sponsored by West Penn Allegheny Health System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
Delayed graft function (DGF) is a major complication following deceased donor renal transplantation. The surgical procedure of harvesting a kidney from a cadaveric donor and implanting the kidney into the recipient inevitably causes some amount of injury. While not always clinically significant, anywhere from 10-50% of transplant patients may develop DGF. Ongoing research in animal models has demonstrated benefit with administration of erythropoietin. The investigators propose to study the effect of Procrit(Epoetin Alfa) on delayed graft function in subjects undergoing kidney transplantation.
Conditions Studied
Interventions
- DRUG Epoetin Alfa
Study Locations (1)
Pennsylvania
- Allegheny General Hospital - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2007-02 |
| Est. Completion | 2010-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00425126
The ClinicalTrials.gov registry entry for NCT00425126 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 362-participant average among 6 other Delayed Graft Function trials with a reported enrollment target (79% lower). The listed sponsor is West Penn Allegheny Health System, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Delayed Graft Function appearing as the primary indexed condition, and to 1 intervention - of which Epoetin Alfa is the first listed.
NCT00425126 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00425126 about?
NCT00425126 is a clinical study titled "Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation". Delayed graft function (DGF) is a major complication following deceased donor renal transplantation. The surgical procedure of harvesting a kidney from a cadaveric donor and implanting the kidney into the recipient inevitably causes some amount of injury. While not always clinically significant, any...
What is the current status of trial NCT00425126?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 76 participants. The study started on 2007-02. Estimated completion is 2010-02.
What conditions does trial NCT00425126 study?
This clinical trial studies the following conditions: Delayed Graft Function.
What interventions are being tested in trial NCT00425126?
The interventions under investigation include: Epoetin Alfa (DRUG).
Who is sponsoring clinical trial NCT00425126?
This trial is sponsored by West Penn Allegheny Health System, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00425126 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Delayed Graft Function
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Envarsus in Delayed Graft Function (E-DGF)
COMPLETED · Phase 4
-
Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation
RECRUITING · Phase 1
-
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
RECRUITING · Phase 3
-
ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function
ACTIVE NOT RECRUITING · Phase 2
-
Deceased Organ Donor Interventions to Protect Kidney Graft Function
COMPLETED · NA
-
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.